'Drug approval process' diaporamas de présentation

Pharmacovigilance

Vladimir Patras, PharmD, MBA. Pharmacovigilance. Clinical Pharmacology Seminar Department of Pharmacology and Toxicology, Faculty of Pharmacy. Vladimir Patras, PharmD, MBA. Withdrawn Drugs (in the US, since 2000) ?.

2.06k views • 52 slides

The Patented Medicines (Notice of Compliance) Regulations

656 views • 43 slides

Biotechnology Regulations

Biotechnology Regulations. Chapter 12. The Regulatory Framework. U.S. Department of Agriculture Safe to Grow Environmental Protection Agency Safe for the Environment Food and Drug Administration Safe to Consume All 3 agencies work together!. U.S. Department of Agriculture.

1.38k views • 24 slides

Drug Unit Medicine and Illegal Drugs Ms. Kramer 8 th Grade Health

214 views • 21 slides

FDA Regulatory Exclusivity and Patent Protection for Drugs

FDA Regulatory Exclusivity and Patent Protection for Drugs. American Intellectual Property Law Assn. IP Practice in Japan Committee October 25-36, 2005 Darryl Webster Wyeth. FDA Regulatory Exclusivity and Patent Protection for Drugs.

401 views • 19 slides

Prescription for Pharmaceutical Reform: Healing an Ailing System

Prescription for Pharmaceutical Reform: Healing an Ailing System. Six Principles of Reform. Access. Medical needs, not finances, should determine access. Affordable. Drugs must be affordable to society. Innovation. Apply innovation to maximizing population health. Health first.

97 views • 9 slides

Catalysts for enactment of PDUFA

280 views • 8 slides

Hepatitis Drugs Market Analysis and Demand Forecast to 2020

The global hepatitis drugs market was valued at $23,222.1 million in 2014, and it is expected to grow with a CAGR of 29.7% during 2015 - 2020. The global hepatitis drugs market is growing due to increasing incidences of hepatitis and increasing support from government organizations.

152 views • 8 slides

Age-related Macular Degeneration Therapeutic Pipeline Analysis 2017

The study analysed that the Age-related related macular degeneration therapeutics pipeline comprises of approximately 55 drug candidates, of which five drug candidates are in the Phase III stage, 12 drug candidates are in Phase II stage, 11 drug candidates are in Phase I, 24 drug candidates are in Pre-clinical stage, and there are three drug candidates which are in Discovery stage.

120 views • 8 slides